Allison Betof Warner, MD, PhD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with stage IIB and beyond melanoma.
Neoadjuvant Pembrolizumab Appears Tolerable in Stage IIIB-D Melanoma
The phase 1/2 KEYMAKER-U02 trial evaluating pembrolizumab alone or as a combination therapy in stage IIIB-D melanoma found no adverse event–related deaths.
Nivolumab/Ipilimumab Continues to Show Survival Benefit in Melanoma
The CheckMate 067 trial found that, at a 10-year follow-up, nivolumab/ipilimumab elicited a median OS of 71.9 months in patients with previously untreated, advanced melanoma.
Pre-BLA Meeting Successful for RP1 Combo in Anti–PD-1–Failed Melanoma
Support for the planned biologics license application comes from data showing a 32.9% response rate with RP1 plus nivolumab for melanoma.
BNT111/Cemiplimab Combo Significantly Improves ORR in Unresectable Melanoma
The safety profile of BNT111 plus cemiplimab was consistent with previous trials assessing BNT111 with anti–PD-L1 treatments.
Dabrafenib/Trametinib Yields Sustained Survival During Long-Term Follow-up in Advanced Melanoma
Continued survival was observed in dabrafenib/trametinib combination after 8 years follow-up in patients with advanced melanoma.
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
Omid Hamid, MD, gives his perspective on the use of tumor-infiltrating lymphocyte therapy for patients with melanoma.